Get the Stockscreener App
4.24
2.30%
-0.10
After Hours:
4.29
0.05
+1.18%
Ardelyx Inc stock is traded at $4.24, with a volume of 3.39M.
It is down -2.30% in the last 24 hours and up +8.16% over the past month.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
See More
Previous Close:
$4.34
Open:
$4.3
24h Volume:
3.39M
Relative Volume:
0.68
Market Cap:
$1.01B
Revenue:
$251.85M
Net Income/Loss:
$-72.58M
P/E Ratio:
-13.53
EPS:
-0.3134
Net Cash Flow:
$-63.80M
1W Performance:
-2.75%
1M Performance:
+8.16%
6M Performance:
-20.90%
1Y Performance:
-23.60%
1-Day Range:
$4.21
$4.36
1-Week Range:
$4.21
$4.47
52-Week Range:
$3.21
$7.18
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
4.24 | 1.04B | 251.85M | -72.58M | -63.80M | -0.3134 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| May-02-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-07-25 | Resumed | Ladenburg Thalmann | Buy |
| Mar-04-25 | Initiated | BTIG Research | Buy |
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
BTIG Remains a Buy on Ardelyx (ARDX) With a $14 PT - Insider Monkey
14 Best Biotech Penny Stocks to Buy Right Now - Insider Monkey
10 Penny Stocks That Will Skyrocket - Insider Monkey
When is Ardelyx Inc. stock expected to show significant growthSwing Trade Picks With Low Risk - jammulinksnews.com
Why is Ardelyx Inc. stock attracting strong analyst attentionDaily Trading Strategy For Smart Trading - jammulinksnews.com
Will Ardelyx Inc. benefit from macro trendsPre-Market Stock Movement Summary and Review - Newser
Ardelyx Races To Grow Sales But Profits Remain Elusive - Finimize
Has Ardelyx Inc. Stock Ever Crashed Historical Volatility ReviewSmart Money Tracking Signal Generator Activated - metal.it
What makes Ardelyx Inc. stock price move sharplyCapital Growth Plan for New Investors - Newser
Does Ardelyx Inc. show high probability of reboundEarly Entry Planner for Swing Candidates - Newser
Ardelyx Inc. Sees Spike in Bullish Option FlowTrade Insight With Community Collaboration Supported - metal.it
Why Ardelyx Inc. is moving todayRisk Aware Trading Ideas with Alert Levels - Newser
Can machine learning forecast Ardelyx Inc. recoveryFree Stable Entry High Return Opportunities - Newser
Ardelyx (ARDX) Appoints New Chief Business and HR Officers - MSN
Ardelyx Inc. Stock Lags Behind Sector BenchmarksWeekly Stock Watch With Growth Focus Expanded - metal.it
How Ardelyx Inc. stock performs during market volatilityTarget Return Focused Trade Insights Shared - metal.it
Earnings Preview: Ardelyx (ARDX) Q2 Earnings Expected to Decline - Yahoo Finance
What is the dividend policy of Ardelyx Inc. stockCapitalize on emerging market opportunities - jammulinksnews.com
What is Ardelyx Inc. company’s growth strategyBuild a portfolio that stands the test of time - jammulinksnews.com
How strong is Ardelyx Inc. company’s balance sheetAchieve rapid capital gains with smart investing - jammulinksnews.com
What catalysts could drive Ardelyx Inc. stock higher in 2025Explosive portfolio gains - jammulinksnews.com
How does Ardelyx Inc. compare to its industry peersFree High-Return Strategy Alerts - jammulinksnews.com
Should I hold or sell Ardelyx Inc. stock in 2025Capitalize on momentum-driven investment opportunities - jammulinksnews.com
How does Ardelyx Inc. generate profit in a changing economyMaximize gains with professional stock picks - jammulinksnews.com
Does Ardelyx Inc. stock perform well during market downturnsGain the edge with real-time market data - jammulinksnews.com
What are Ardelyx Inc. company’s key revenue driversConsistently profitable trades - jammulinksnews.com
Is Ardelyx Inc. a good long term investmentPhenomenal investment performance - Autocar Professional
What analysts say about Ardelyx Inc. stockMassive portfolio appreciation - Autocar Professional
Ardelyx Inc. Stock Analysis and ForecastExceptional portfolio growth - Autocar Professional
Ardelyx (ARDX) Announced New data for IBSRELA - MSN
What drives Ardelyx Inc. stock priceFree Stock Market Trend Analysis - Autocar Professional
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), TG Therapeutics (TGTX) and Ardelyx (ARDX) - The Globe and Mail
Ardelyx, Inc.'s (NASDAQ:ARDX) Price Is Right But Growth Is Lacking After Shares Rocket 28% - 富途牛牛
11 Best American Penny Stocks to Buy According to Analysts - Insider Monkey
5 stocks with growth potential: SOUN, JBL, MNTN, ARDX, RCEL - Markets.com
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):